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Aortic Valve Replacement
A Prospective Randomized Evaluation of Mechanical
Versus Biological Valves in Patients Ages 55 to 70 Years
Paolo Stassano, MD,* Luigi Di Tommaso, MD,* Mario Monaco, MD,† Francesco Iorio, MD,*
Paolo Pepino, MD,† Nicola Spampinato, MD,* Carlo Vosa, MD*
Naples and Castelvolturno, Italy
Objectives The aim of this study was to determine long-term results between bioprosthetic (BP) and mechanical (MP) aortic
valves in middle-aged patients.
Background It has not been established which is the best aortic valve substitute in patients ages 55 to 70 years. We con-
ducted a randomized study to compare long-term outcomes between BP and MP aortic valves.
Methods Between January 1995 and June 2003, 310 patients were randomized to receive a BP or an MP aortic valve.
Primary end points of the study were survival, valve failure, and reoperation.
Results One hundred fifty-five patients received a BP valve, and 155 patients received an MP valve. Four patients died,
perioperatively, in the MP group (2.6%), and 6 patients died in the BP group (3.9%, p  0.4). At late follow-up
(mean 106  28 months) 41 patients died in the MP group and 45 patients died in the BP group (p  0.6).
There was no difference in the survival rate at 13 years between the MP and BP groups. Valve failures and reop-
erations were more frequent in the BP group compared with the MP group (p  0.0001 and p  0.0003, re-
spectively). There were no differences in the linearized rate of thromboembolism, bleeding, endocarditis, and
major adverse prosthesis-related events (MAPE) between the MP and BP valve groups.
Conclusions At 13 years, patients undergoing aortic valve replacement either with MP or BP valves had a similar survival rate
as well the same rate of occurrence of thromboembolism, bleeding, endocarditis, and MAPE, but patients who
had undergone aortic valve replacement with BP valves faced a significantly higher risk of valve failure and
reoperation. (J Am Coll Cardiol 2009;54:1862–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.032c
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7ccording to the Adult Cardiac Surgery Database, in the
.S. 17,592 aortic valve replacements (AVRs) and 14,957
VRs with concomitant coronary artery bypass graft
CABG) were performed in 2007 (personal communica-
ion, STS Adult Cardiac Surgery National Database, The
ociety of Thoracic Surgeons, Chicago, Illinois, May,
008). Usually these patients arrive at surgery already
nowing the type of valve best suited to them, because they
ave had a thorough conversation with the cardiac surgeon.
evertheless, in clinical practice we encounter patients who,
ven after a detailed explanation concerning the pros and
ons of the mechanical (MP) and biological (BP) valves, are
affled about the decision and leave the responsibility of
heir valve choice entirely to the surgeon’s experience.
But, although there is wide consensus on the type of valve
o be put in younger and in older patients, aortic valve
rom the *Cardiac Surgery Unit, University Federico II, School of Medicine, Naples,
taly; and the †Cardiac Surgery Unit, Istituto Clinico Pineta Grande, Castelvolturno,
taly.a
Manuscript received November 14, 2008; revised manuscript received June 22,
009, accepted July 28, 2009.hoice in the ages between 55 and 70 years is very
ifficult, because in this age span patients are no longer
ruly young and not yet truly old. This is the “threshold
ge” where it is difficult to balance the risk of the
nticoagulation therapy with the need for a reoperation
1); furthermore, this age span comprises a consistent
umber of patients in need of AVR, and as of 2006, the
merican College of Cardiology/American Heart Asso-
iation Practice Guidelines do not shed clear light on the
est valve choice (2).
See page 1869
Therefore, we thought that in this particular age group
nd only with patients who left the choice of their valve to
he surgeon, a randomization would be possible and
eaningful.
In this study we investigated clinical outcomes after a
andomized insertion of a BP or MP aortic valve in 55- to
0-year-old patients who dictated to us the choice of their
ortic prosthesis.
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November 10, 2009:1862–8 Aortic Valve Replacement: A Prospective Evaluationethods
rom January 1995 to June 2003, 1,120 patients ages 55
o 70 years underwent AVR at 2 centers. Seven hundred
wenty-eight patients (65%), after an exhaustive conver-
ation with the surgeon, had a clear idea of which valve
ype they wanted, whereas 392 patients (35%) were still
esitant about the valve choice. To these patients we ex-
lained in detail the aim of our study. After adequate
transthoracic and/or transesophageal) echocardiographic
xamination, 31 patients with an aortic annulus 21 mm
ere excluded. Thirty-four patients, although wavering,
id not give their consent to participate in the study,
hereas 327 patients accepted. After written consent was
btained, a closed envelope (containing a letter “M” for
echanical or a letter “B” for biological) was opened, and
he type of prosthesis was told to the patient at least
4 h before surgery; therefore the patient was fully aware
f the type of valve chosen. Seventeen patients were
urther excluded either because they subsequently
hanged their mind (n  10) or because of annulus
ismatch at surgery (n  7). Thus, 310 patients formed
he basis of our study.
A power calculation estimated that approximately 155
atients/group were required to have a minimum of 80%
ower to detect a 10% difference in mortality between the 2
roups with a 2-sided alpha of 0.05. This power calculation
ssumed a probability of death at 10 years after AVR to be
pproximately 60% (3).
Patients considered for this study had not undergone
revious cardiac surgery procedures, did not have active
ndocarditis, did not have aortic root disease, and did not
ave contraindications to warfarin anticoagulation. Only
ingle AVR patients with or without CABG were enrolled
n the grounds that concomitant procedures (mitral and/or
ricuspid, ascending aorta) might significantly increase the
perative risk and make the results more difficult to inter-
ret. Patients with concomitant CAGB were included,
ecause they constitute a large fraction of those undergoing
VR in our center as well as in others (4–6). Because we
ould randomize only patients who dictated their valve
hoice to us, to reach a meaningful number of patients,
hese were enrolled in 2 centers whose surgeons had
eceived the same surgical training and shared the same
urgical indications. The protocol was approved by the
nstitutional review board, and each patient provided writ-
en informed consent before enrollment.
During the 8-year period of this study, the following
ortic bioprostheses were used: 93 Carpentier-Edwards
AV (Edwards Lifesciences, Irvine, California) and 62
arpentier-Edwards Pericardial. The aortic MPs used were:
07 St. Jude Medical (St. Jude Medical, Inc., St. Paul,
innesota) and 48 CarboMedics (Sorin SpA, Milan, Italy).
hese valves were chosen because they were the most
ommonly used at our centers. WThe AVR was undertaken
hrough a median sternotomy,
ith standard cardiopulmonary
ypass under mild hypothermia
32°C), with cold blood cardio-
legia. All valves (either BP or
P) were implanted with inter-
upted horizontal mattress su-
ures with pledgeted 2-0 non-
bsorbable braided polyester.
Patients with aortic MPs post-
peratively received lifelong
arfarin anticoagulation, with a
arget of the international nor-
alized ratio (INR) of 2.0 to 2.5.
atients with aortic bioprosthe-
es received warfarin as an anti-
oagulant for 8 to 12 weeks only
ith the same target of INR.
Patients were seen annually by a cardiac surgeon of our
eams. Missing information was completed with the pa-
ient’s physician and/or his or her family. The follow-up was
losed on June 2008 and was 98.6% complete.
tudy end points. Primary study end points were survival,
tructural valve deterioration (defined as valve failure), and
eoperation. We reported overall, cardiac-related, and valve-
elated mortality. Sudden, unexplained deaths were in-
luded in valve-related mortality.
Secondary end points were the occurrence of major
dverse prosthesis-related events (MAPE): thromboembo-
ism, bleeding, endocarditis, structural valve deterioration,
nd nonstructural dysfunction (pannus and paravalvular
eak).
These complications were defined according to the guide-
ines for reporting mortality and morbidity after cardiac
alve intervention (7).
tatistical analysis. Continuous data are presented as
ean  SD. The Fisher exact test (for sparse data) or
hi-square test was used to compare categorical variables,
hereas t tests (Mann-Whitney U test) were used to
ompare continuous variables between valve groups.
wo-tailed tests of significance are reported, and p values
0.05 are considered statistically significant. The rate of
alve-related events, such as thromboembolism, bleeding,
nd valve failure, was calculated with linearized rates
xpressed as events/100 patient-years of follow-up and
eported with a 95% confidence interval. The likelihood
atio test was used to compare the linearized rates
etween the valve groups. A Cox proportional hazard
egression model was used to analyze a set of time-
ependent covariates associated with late cardiac-related
ortality. Kaplan-Meier analysis was used to study pa-
ient survival and event-free status, with the log-rank test
Cox-Mantel) to ascertain differences between the
roups. Data were analyzed by SPSS version 14.0 for
Abbreviations
and Acronyms
AVR  aortic valve
replacement
BP  biological prosthesis
CABG  coronary artery
bypass graft
INR  international
normalized ratio
MAPE  major adverse
prosthesis-related events
MP  mechanical
prosthesis
NYHA  New York Heart
Association
VA  Veterans
Administrationindows (SPSS, Inc., Chicago, Illinois).
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atient variables, including clinical characteristics, are de-
icted in Table 1. There were no clinical or periprocedural
ifferences between the MP and BP groups. In both groups,
edian valve size implanted was 23 mm. Four patients died,
erioperatively (30 days), in the MP group (2.6%), and 6
atients died in the BP group (3.9%, p  0.4). Causes of
ospital mortality and early complications are depicted in
able 2.
Pre-Operative and Perioperative Patient CharactTable 1 Pre-Operative and Perioperative Pat
Variables MP (n
Age, yrs 64.0
Male 66
NYHA functional class 3.0
NYHA functional class III or IV 119
Diabetes 23
COPD 43
Renal failure 10
Peripheral vascular disease 21
EF pre-operative (%) 47.8
EF 30% 12
Urgent or emergency status 11
Coronary artery disease 41
Previous myocardial infarction 8
Median valve size, mm 2
CABG 36
Cardiopulmonary bypass time, min 74.2
Aortic cross-clamp time, min 53.5
Values are presented as mean  SD or n (%).
BP  biological prosthesis; CABG  coronary artery bypass graftin
MP  mechanical prosthesis; NYHA  New York Heart Association.
Hospital ResultsTable 2 Hospital Results
Variables MP (
Hospital mortality 4
Causes
Perioperative myocardial infarction 1
Low cardiac output syndrome 2
Cerebrovascular accident 1
Pulmonary complications
Complications
Inotropic support 54
Intra-aortic balloon pump 2
Myocardial infarction 6
Neurological complications 6
Respiratory complications 11
Prolonged intubation (48 h) 13
Renal failure 2
Blood losses (ml) 690
Reoperation for bleeding 3
ICU stay, days 2.2
Prolonged ICU stay (10 days) 3
LOS, days 6.8Values are presented as n (%) or mean  SD.
ICU  intensive care unit; LOS  length of stay; other abbreviations as in TAt late follow-up (range 43 to 161 months, mean 106 
8 months), 41 patients died in the MP group and 45
atients died in the BP group (p  0.6). Overall mortality,
auses of mortality, and the occurrence of MAPE are given in
able 3. Linearized rates of valve-related events are shown in
able 4. There were no differences in linearized rate of
hromboembolism, bleeding, endocarditis, valve thrombo-
is, and occurrence of MAPE between the MP and BP valve
roups, although a statistical trend (p  0.08) for increased
leeding in the MP group was noted.
icsCharacteristics
) BP (n  155) p Value
63.5 3.9 0.4
78 (50.3) 0.2
3.0 0.7 0.9
117 (75.5) 0.9
19 (12.3) 0.6
39 (25.2) 0.7
8 (5.2) 0.8
18 (11.6) 0.7
48.7 9.8 0.3
11 (7.1) 0.8
12 (7.7) 0.9
52 (33.5) 0.5
11 (7.1) 0.6
23 1
43 (27.7) 0.4
73.5 9.9 0.5
52.9 9.3 0.6
D  chronic obstructive pulmonary disease; EF  ejection fraction;
5) BP (n  155) p Value
6 (3.9) 0.4
2 (1.3) 0.5
3 (1.9) 0.5
0.5
1 (6.4) 0.5
61 (39.3) 0.5
4 (2.6) 0.5
8 (5.2) 0.8
5 (3.2) 0.9
13 (8.4) 0.8
9 (5.8) 0.5
1 (6.4) 0.5
0 730 290 0.3
4 (2.6) 0.5
2.3 0.7 0.2
4 (2.6) 0.5
6.9 1.2 0.1eristient
 155
7.6
(42.5)
1.3
(76.8)
(14.8)
(27.7)
(6.5)
(13.5)
12.0
(7.7)
(7.1)
(26.4)
(5.2)
3
(23.2)
9.2
10.8n  15
(2.6)
(6.4)
(1.3)
(6.4)
(34.9)
(1.3)
(3.9)
(3.9)
(7.1)
(8.4)
(1.3)
 34
(1.9)
 0.6
(1.9)
 1.1able 1.
i
w
o
3
o
g
a
t
s
t
0
p
g
w
w
(
B
0
H
m
l
t
0
a
s
d
a
v
D
T
y
i
a
r
i
r
v
t
d
r
v
i
i
u
v
c
t
r
d
t
n
c
a
h
s
d
n
t
c
t
t
M
t
(
s
L
M
a
CI
A
L
C
1865JACC Vol. 54, No. 20, 2009 Stassano et al.
November 10, 2009:1862–8 Aortic Valve Replacement: A Prospective EvaluationAt follow-up, we also observed that, although all patients
n the MP group were receiving lifelong anticoagulation
ith warfarin sodium, in the BP group a substantial number
f patients, 31 (21.1%), were receiving warfarin sodium, and
8 (25.8%) were receiving antiaggregation with ticlopidine
r aspirin at discretion of the treating physician. In this BP
roup, 5 patients with warfarin (16.1%), 3 patients with
ntiaggregation (7.9%), and 1 patient without anticoagula-
ion/antiaggregation (1.3%) suffered from bleeding epi-
odes. There was no difference in bleeding between patients
aking warfarin and patients taking antiaggregation (p 
.2), whereas there was difference in bleeding between
atients taking warfarin versus other patients of the same
roup (p  0.02). The bleeding rate in patients with BP
ho were not receiving warfarin, 4 of 116 patients (3.4%),
as less than in patients with MP with warfarin, 19 of 149
12.7%) (p  0.001).
Valve failures and reoperations were more frequent in the
P group compared with the MP group: p 0.0001 and p
.0003, respectively (Table 4).
Cox hazard regression showed that worse New York
eart Association functional class (p  0.01), adjunct of
yocardial revascularization procedures (p  0.001), and
ow ejection fraction (p  0.05) were independent predic-
ors of late mortality (Table 5).
At 160 months there were no differences in overall (p 
.2) and cardiac-related mortality (p  0.3) between MP
nd BP (Figs. 1 and 2).
Occurrence of all MAPE, although never reaching a
ignificant difference between MP and BP (0.1), started to
iverge beginning at 10 years (Fig. 3), when valve failures
nd reoperations became significantly more frequent in BP
alve recipients compared with MP valve recipients.
ate ResultsTable 3 Late Results
Variables MP (n  149) BP (n  147) p Value
Overall mortality 41 (27.5%) 45 (30.6%) 0.6
Cardiac-related mortality 25 (16.7%) 32 (21.7%) 0.3
Valve related mortality 10 (6.7%) 12 (8.1%) 0.8
MAPE 35 (23.4%) 42 (28.6%) 0.4
APE  major adverse prosthesis-related events (valve-related mortality not included); other
bbreviations as in Table 1.
inearized Rate of Valve-Related EventsTable 4 Linearized Rate of Valve-Related Events
Variables
MP (n  149)
%/pt-yr (95% CI)
BP (n  147)
%/pt-yr (95% CI) p Value
Thromboembolism 0.54 (0.14–0.94) 0.24 (0.03–0.51) 0.3
Bleeding 1.47 (0.81–2.13) 0.72 (0.25–0.19) 0.08
Endocarditis 0.38 (0.04–0.72) 0.24 (0.03–0.51) 0.7
Valve failure 0 2.17 (1.35–2.98) 0.0001
Valve thrombosis 0.23 (0.03–0.49) 0 0.2
Nonstructural dysfunction 0.23 (0.03–0.49) 0.24 (0.03–0.51) 0.6
Reoperation 0.62 (0.19–1.05) 2.32 (1.48–3.18) 0.0003BI  confidence interval; other abbreviations as in Table 1.iscussion
his prospective study of 310 patients between 55 and 70
ears of age who underwent AVR with MPs and BPs
ndicates that: 1) overall mortality is similar between MP
nd BP groups; 2) the incidences of valve failures and
eoperations are greater in the BP group; and 3) the
ncidence of MAPE is similar in MP and BP groups.
Randomized clinical trials represent the best evidence
egarding the relative risks and benefits of tissue and MP
alves, because they avoid bias and confounding incidental
o nonrandomized studies. But randomized studies are
ifficult to carry out, because patients in need of valve
eplacement arrive at surgery already knowing the type of
alve chosen. Therefore, these patients cannot be forced
nto a randomized study. At the same time, even in the case
n which the choice is left to the surgeon’s experience,
sually surgeons prefer MP valves in young patients and BP
alves in older patients, although there might be important
omorbidities or other patient preferences that favor one
ype or another prosthetic valve. Therefore, we could
andomize only middle-aged patients in whom it is really
ifficult to balance the risk of anticoagulation therapy with
he need for a reoperation. This age span comprises a large
umber of patients in need of AVR (4–6).
There have been only 2 randomized studies that have
ompared survival and valve-related complications associ-
ted with the use of MP or BP valves, and these studies have
elped physicians in the choice of the type of valve best
uited to their patients (2,3,8–10). However, these studies
id not focus on a specific age group, had a considerable
umber of redo-sternotomy patients at initial valve opera-
ion, had a perioperative mortality not acceptable for the
urrent times, and dealt with valve types no longer in use,
hus potentially biasing the choice of one valve type versus
he other.
ortality. In our study there were no differences in mor-
ality at 5, 10, and 13 years. In the Veterans Administration
VA) Study, patients who underwent AVR with MPs had a
ignificantly lower 15-year mortality rate than those with a
ox Hazards Regression:ndependent Predictors of Late MortalityTable 5 Cox Hazards Regression:Independent Predictors of Late Mortality
Covariates p Value
Hazard
Ratio 95% CI
Age 0.7 1.010 0.947–1.077
Sex 0.8 0.960 0.580–1.587
Mechanical valve 0.2 0.730 0.446–1.196
NYHA functional class 0.01 1.063 1.018–1.060
Urgent or emergency operation 0.7 1.172 0.506–2.713
Low EF 0.05 1.476 1.034–2.107
CABG 0.001 3.472 2.063–5.844
Diabetes mellitus 0.5 0.784 0.382–1.608
COPD 0.1 1.915 0.828–4.432
Chronic renal failure 0.9 1.050 0.388–2.843
bbreviations as in Table 1.P valve (8). In the Edinburgh Heart Valve Trial, at 12
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Aortic Valve Replacement: A Prospective Evaluation November 10, 2009:1862–8ears there was a survival advantage of the MP valve group
ompared with the BP valve group, but this advantage
isappeared at 20 years (10). Brown et al. (5), in a 1-to-1
tudy, matched patients age 50 to 70 years who had
ndergone AVR and found a 10-year survival of 68% in the
P group and 50% in the BP group (p  0.1). Also, Lund
nd Bland (4) in a meta-analysis with regression analyses
id not find significant differences in the death rate between
P and BP valves when corrected for age.
Figure 1 Overall Survival of Patients Who Received Either MP o
BP  biological prosthesis; MP  mechanical prosthesis.
Figure 2 Cardiac-Related Survival of Patients Who Received Ei
Abbreviations as in Figure 1.alve failure and reoperation. In our study the only
ifference between MP and BP valves was related to valve
ailures and reoperations, both events penalizing the
ioprostheses.
In the VA randomized study the incidences of primary
alve failure and reoperation after AVR were significantly
reater in the BP valve group (p  0.0001 and p  0.0003,
espectively) (8). In the 20-year Edinburgh trial, reoperation
as more common in BP aortic valve patients compared
Valves
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November 10, 2009:1862–8 Aortic Valve Replacement: A Prospective Evaluationith MP aortic valve patients (p  0.0001) (10). Freedom
rom reoperation on the aortic valve was not significantly
ifferent between MP and BP valve patients at 10 years in
he 1-to-1 matched patients study of Brown et al. (5). We
bserved that the risk of valve failure with consequent
eoperation begins to rise by 10 years and increases progres-
ively with time, without observing a leveling off or reduc-
ion in risk of tissue valve failure. Khan et al. (11) in a
0-year comparison of tissue and MP valve found similar
esults.
ther valve-related complications. The linearized inci-
ence of the other prosthesis-related events (i.e., thrombo-
mbolism, bleeding, endocarditis, and valve thrombosis)
ailed to show differences between the 2 types of valve.
Interestingly, we did not find differences in the rate of
leeding between MPs and BPs, although we observed a
rend (p  0.08) toward increased bleeding in the MP
roup. Hammermeister et al. (8) in the VA trial observed a
reater bleeding rate in the MP aortic group than in the BP
ortic group (p  0.0001). Also, in the Edinburgh trial, the
ncidence of all episodes (major and minor) of bleeding was
ignificantly higher in the MP aortic valve group compared
ith the BP aortic valve group (10). Brown et al. (5)
bserved hemorrhagic complications in 15% of patients
ith MP valves and in 7% with BP valves (p  0.01). The
ack of difference in bleeding episodes between MP and BP
alves might be ascribed either to our low-intensity antico-
gulation in MP valve patients or to the fact that in the BP
alve patients group a significant number of patients were
eceiving warfarin sodium or antiaggregation at late follow-
p. Our anticoagulation protocol with a target of the INR of
.0 to 2.5 is somewhat less than that usually recommended,
Figure 3 Freedom From MAPE for Patients Who Received Eithe
MAPE  major adverse prosthetic-related events; other abbreviations as in Figurend this lower INR target might have implications regard- ong the ability to extrapolate these data to other sites. In 2
andomized trials with prosthetic heart valves, low-intensity
nticoagulation resulted in a lower bleeding rate than in
atients with the standard dose of anticoagulation (12,13).
ith increasing time from operation, a greater number of
ur BP valve replacement patients were placed on antico-
gulation/antiaggregation therapy by their cardiologist
nd/or physician due to many causes: atrial fibrillation,
ransient ischemic attack, chamber enlargement, and so on.
herefore, implantation of a BP valve does not ensure that
n the future the patient will avoid anticoagulation/
ntiaggregation and does not protect the patient from the
normal” occurrence of gastrointestinal, urogenital, and
erebral bleeding (4).
The incidence of thromboembolism did not differ be-
ween the 2 groups, underscoring the efficacy of the anti-
oagulation regimen and maybe disproving the concept that
ioprostheses are associated with a lower embolic rate. A
ossible explanation is that, as tissue valves deteriorate, they
ight become a source for thromboembolism (14); other
auses might be the insurgence of atrial fibrillation, enlarge-
ent of heart chambers associated with low ejection frac-
ion, and so on.
There is uncertainty as to whether the adjunct of coronary
evascularization in patients undergoing AVR leads to
ong-term survival similar to that of patients without coro-
ary revascularization requiring AVR. In the present report,
he adjunct of a myocardial revascularization procedure
nfluenced late mortality. Kvidal et al. (15) observed that
atients with concomitant AVR and CABG showed de-
reased long-term survival. However, these patients were
or BP Valvesr MP
1.lder at the time of operation. Consequently, age adjust-
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Aortic Valve Replacement: A Prospective Evaluation November 10, 2009:1862–8ent reduced the effect on observed survival, and there was
o significant difference in relative survival (15).
tudy limitations. Due to our randomization protocol, the
opulation sizes were small. Thus, the power to comment
n clinical events might be somewhat limited.
All post-operative medications were at the discretion of
he treating physician and, therefore, might have impacted
he clinical outcomes differently in the 2 groups.
Patient quality of life was not measured, and this might
e an important limitation of this study.
onclusions
VR with MP valves in middle-aged patients seems to be
n advantageous solution. Further investigation and data
ollection will allow the assessment of valve performance
nd the quality of life that they offer over a more extended
eriod of time.
eprint requests and correspondence: Dr. Paolo Stassano, Via
ramante, 19, 81100 Caserta, Italy. E-mail: pstassano@libero.it.
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